# US 2020/0369742 A1 · Novel t-cell receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369742 A1
- Document ID: US20200369742A1
- Status: Published application
- Kind: A1
- Application number: 16/858,082
- Filed: 2020-04-24
- Published: 2020-11-26
- Earliest claimed: 2017-10-26
- Assignees: University College Cardiff Consultants Limited
- Applicants: University College Cardiff Consultants Ltd.
- Inventors: Andrew SEWELL; Garry DOLTON
- Web page: https://patentgrep.com/patent/US20200369742A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.

## Claims

### Claim 1

A vector encoding a tumour specific T-cell receptor (TCR) wherein the TCR comprises (i) an a chain having three a chain complementarity-determining regions (CDRs) comprising the sequences: TSESDYY (SEQ ID NO:3) as CDR1α, ATEN (SEQ ID NO:4) as CDR2α and CAYRSAVNARLMF (SEQ ID NO: 1) as CDR3α and (ii) a 13 chain having three 13 chain CDRs comprising the sequences: MGHDK (SEQ ID NO:5) as CDR113, SYGVNS (SEQ ID NO:6) as CDR2β and CASSEARGLAEFTDTQYF (SEQ ID No: 2) as CDR3β.

### Claim 2 (depends on 1)

The vector according to claim 1 wherein said a chain comprises the amino acid sequence:
(SEQ ID NO: 7)
AQTVTQSQPEMSVQEAETVTLSCTYDTSESDYYLFWYKQPPSRQMILVIR
QEAYKQQNATENRFSVNFQKAAKSFSLKISDSQLGDAAMYFCAYRSAVNA
RLMFGDGTQLVVKPNIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQ
SKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDT
FFPSPESS
or a sequence that shares at least 95% identity therewith.

### Claim 3 (depends on 1)

The vector according to claim 1 wherein said β chain comprises the amino acid sequence:
(SEQ ID NO: 8)
EADIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLIHYSY
GVNSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCASSEARGLA
EFTDTQYFGPGTRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLA
TGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVS
ATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD
or a sequence that shares at least 95% identity therewith.

### Claim 4 (depends on 1)

The vector encoding the tumour specific T-cell receptor (TCR) according to claim 1 wherein said TCR is MR1-restricted.

### Claim 5

A T-cell comprising a vector encoding a tumour specific T-cell receptor (TCR) wherein the TCR comprises (i) an a chain having three a chain complementarity-determining regions (CDRs) comprising the sequences: TSESDYY (SEQ ID NO:3) as CDR1α, ATEN (SEQ ID NO:4) as CDR2α and CAYRSAVNARLMF (SEQ ID NO: 1) as CDR3α and (ii) a β chain having three β chain CDRs comprising the sequences: MGHDK (SEQ ID NO:5) as CDR1β, SYGVNS (SEQ ID NO:6) as CDR2β and CDR CASSEARGLAEFTDTQYF (SEQ ID No: 2) as CDR3β and wherein the T-cell expresses said TCR.

### Claim 6 (depends on 5)

A pharmaceutical composition comprising the T cell according to claim 5.

### Claim 7 (depends on 5)

A method of treating cancer in an individual to be treated comprising administering to said individual the T-cell according to claim 5.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said cancer is selected from the group consisting of colorectal cancer, lung, kidney, prostrate, cervical, skin melanoma, bone, breast, ovarian and blood cancer.

### Claim 9 (depends on 7)

The method according to claim 7, wherein said T-cell is administered in combination with an anti-tumour agent.

### Claim 10 (depends on 1)

The vector according to claim 1, wherein the TCR is a chimeric TCR.

### Claim 11 (depends on 1)

The vector according to claim 1, which is a lentiviral vector.

### Claim 12 (depends on 2)

The vector according to claim 2, wherein said 13 chain comprises the amino acid sequence:
(SEQ ID NO: 8)
EADIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLIHYSY
GVNSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCASSEARGLA
EFTDTQYFGPGTRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLA
TGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVS
ATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD
or a sequence that shares at least 95% identity therewith.

### Claim 13 (depends on 12)

The vector according to claim 12, wherein said a chain comprises the sequence of SEQ ID NO: 7 or a sequence that shares at least 98% identity therewith and said β chain comprises the sequence of SEQ ID NO: 8 or a sequence that shares at least 98% identity therewith.

### Claim 14 (depends on 12)

The vector according to claim 12, which is a lentiviral vector.

### Claim 15 (depends on 5, 12)

The T-cell according to claim 5 wherein said vector is the vector according to claim 12.

### Claim 16 (depends on 5, 14)

The T-cell according to claim 5 wherein said vector is the vector according to claim 14.

### Claim 17 (depends on 7, 15)

The method of treating cancer according to claim 7, wherein the T-cell is the T-cell according to claim 15.

### Claim 18 (depends on 17)

The method according to claim 17 wherein said cancer is selected from the group consisting of colorectal cancer, lung, kidney, prostrate, cervical, skin melanoma, bone, breast, ovarian and blood cancer.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the vector according to claim 1.
